Ciraparantag-d8 (tetra (hydrochloride) diacetate)

Ciraparantag-d8 (PER977-d8) tetrahydrochloride diacetate is the deuterium labeled Ciraparantag (HY-18660) . Ciraparantag is a thrombin and factor Xa inhibitor. Ciraparantag is a broad-spectrum reversal agent for anticoagulants, including low-molecular-weight heparin, unfractionated heparin, and certain direct oral anticoagulants. It is reported to antagonize the effects of all coagulants except VKAs and agratroban[1][2][3][4].

Product Specifications

Product Name Alternative

PER977-d8 (tetrahydrochloride diacetate)

UNSPSC

12352005

Target

Factor Xa; Isotope-Labeled Compounds; Thrombin

Related Pathways

Metabolic Enzyme/Protease; Others

Applications

Neuroscience-Neuromodulation

Field of Research

Cardiovascular Disease

Smiles

O=C(NCCCN1C([2H])([2H])C([2H])([2H])N(CCCNC([C@@H](N)CCCNC(N)=N)=O)C([2H])([2H])C1([2H])[2H])[C@@H](N)CCCNC(N)=N.CC(O)=O.CC(O)=O.Cl.Cl.Cl.Cl

Molecular Formula

C26H52D8Cl4N12O6

Molecular Weight

786.69

References & Citations

[1]Das A, et al. Novel antidotes for target specific oral anticoagulants. Exp Hematol Oncol. 2015 Sep 15;4:25.|[2]Gomez-Outes A, et al. Specific antidotes in development for reversal of novel anticoagulants: a review. Recent Pat Cardiovasc Drug Discov. 2014;9 (1) :2-10.|[3]Hu TY, et al. Reversing anticoagulant effects of novel oral anticoagulants: role of ciraparantag, andexanet alfa, and idarucizumab. Vasc Health Risk Manag. 2016 Feb 17;12:35-44.|[4]Honickel M, et al. The Reversal of Direct Oral Anticoagulants in Animal Models. Shock. 2017 Aug;48 (2) :144-158.